$20m-$39.9m

Taiho Ventures has supplied a $10m extension for Caltech spinout Axial Biotherapeutics’ series B, bringing the total to $35m.

University of Virginia-founded batteryless industrial IoT monitor developer Everactive was previously known as PsiKick, and has now raised a total of $63m in equity funding.

KU Leuven's autoimmune disease therapy developer Imcyse, which is targeting type 1 diabetes, has raised close to $39m in equity and debt financing in its latest effort.

Roche participated in the Agilent Technologies-led round, which will fund the launch of Stanford spinout Purigen's isotachophoresis-based DNA and RNA sample preparation platform.

Lidar technology developer Sense Photonics has emerged from stealth with $26m in series A funding from investors co-led by the UC-backed Congruent Ventures.

OncoMyx Therapeutics was co-founded by ASU's Grant McFadden and will use the series A funding to advance the development of its lead asset aimed at several indications of cancer.

Tel Aviv University announces $20m commercialisation fund with Tata Industries.

Invesco Perpetual, the fund manager, and Imperial Innovations, the London Stock Exchange-listed spin-off from Imperial College London, are joined by The Cancer Prevention and Research Institute of Texas and the Wellcome Trust supporting Cell Medica's growth.

Revolymer, which makes chewing gum that is easier to remove from streets and pavements, was backed by the Setsquared Partnership, a joint venture capital initiative between Bath, Bristol, Exeter, Southampton and Surrey.